Bruker Introduces Breakthrough MALDI-2 Source on timsTOF fleX, and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF

▤ Summary

BILLERICA, Mass.--(BUSINESS WIRE)--At the virtual ASMS 2020 Reboot conference, Bruker Corporation (Nasdaq: BRKR) today announces a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world’s first commercial MALDI-2 post-ionization (PI) source, which is now available as an option on the timsTOF fleX™ ESI/MALDI mass spectrometer. With its dramatically increased sensitivity and accessible range of chemical classes, the novel MALDI-2 source option can now further enhance mass spectrometry-based, non-targeted tissue analysis.” Bruker now also offers a MALDI-2 compound reference library for its MetaboScape® metabolomics software, which was created during various academic and pharma collaborations. The sensitivity and speed of prm-PASEF already rivals that of PRM methods that have been developed over many years on other platforms.” Dr. Jarrod Marto, Associate Professor at the Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women’s Hospital added: “We have made tremendous progress since initiating co-development of prm-PASEF with the Bruker Team. Moreover, real-time adjustment of acquisition parameters with prm-PASEF LIVE will push usability and throughput even further.” Peptide collisional cross sections (CCS) measured at large scale and with high precision by the unique TIMS technology deliver added dimensionality for increased confidence of identification in 4D proteomics. We are committed to our strategy of open data file formats to facilitate community-driven software development, including our third-party partners through API access for the benefit of the timsTOF user community.” Featured speakers at our eXceed symposia and breakfast events.

▦ Linked Companies

Bruker

$1B+